Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
44.97(c) 45.35(c) 45.06(c) 44.17(c) 43.73 Last
437 900 484 060 496 088 1 320 376 607 808 Volume
+3.62% +0.85% -0.64% -1.98% -1.00% Change
More quotes
Estimated financial data (e)
Sales 2021 564 M 660 M 660 M
Net income 2021 74,0 M 86,7 M 86,7 M
Net Debt 2021 61,0 M 71,5 M 71,5 M
P/E ratio 2021 97,1x
Yield 2021 -
Sales 2022 647 M 758 M 758 M
Net income 2022 42,6 M 49,9 M 49,9 M
Net Debt 2022 93,5 M 110 M 110 M
P/E ratio 2022 166x
Yield 2022 -
Capitalization 7 281 M 8 547 M 8 529 M
EV / Sales 2021 13,0x
EV / Sales 2022 11,4x
Nbr of Employees 3 914
Free-Float 87,1%
More Financials
Company
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug... 
More about the company
Ratings of Evotec SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about EVOTEC SE
09/15EVOTEC : publishes DDup 11 – AI-driven antibody discovery at Evotec
PU
09/06EVOTEC PARTNER BAYER : Phase IIb trial shows eliapixant significantly decreases ..
PU
09/02KAZIA THERAPEUTICS : Evt801 phase i study receives full regulatory approval
AQ
09/02EVOTEC : and Secarna Pharmaceuticals expand strategic partnership in the field o..
PU
09/02PRESS RELEASE : Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals a..
DJ
09/02Secarna Pharmaceuticals and Evotec Expand Strategic Partnership in the Field ..
CI
09/02KAZIA THERAPEUTICS : Secures French Regulatory Approval for Phase 1 Trial of Can..
MT
09/02EVOTEC : partner Kazia Therapeutics announces full regulatory approval for Phase..
PU
09/02EVOTEC : announces Bristol Myers Squibb opt-in of EVT8683 as the first programme..
PU
09/02EVOTEC : announces Bristol Myers Squibb opt-in of EVT8683 as the first programme..
EQ
09/02PRESS RELEASE : Evotec announces Bristol Myers -2-
DJ
09/02PRESS RELEASE : Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the f..
DJ
09/02Evotec SE Announces Bristol Myers Squibb Opt-In of Evt8683 as the First Progr..
CI
09/01Evotec SE english
DJ
08/31DGAP-NVR : Evotec SE: Release according to Article 41 of the WpHG [the German Se..
DJ
More news
News in other languages on EVOTEC SE
09/15EVOTEC : veröffentlicht DDup 11 - "AI-driven antibody discovery at Evotec"
09/13Tagesvorschau international
09/13TAGESVORSCHAU : Termine am 13. September 2021
09/10TAGESVORSCHAU : Termine am 13. September 2021
09/03EVOTEC IM FOKUS : Master of the Forschung im Börsenorbit
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 44,17 €
Average target price 40,01 €
Spread / Average Target -9,41%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Iris L÷w-Friedrich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE45.87%8 547
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420